cabergoline ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
ergot alkaloid derivatives 460 81409-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cabergoline
  • dostinex
  • galastop
  • cabaser
  • cabaseril
An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.
  • Molecular weight: 451.62
  • Formula: C26H37N5O2
  • CLOGP: 4.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 71.68
  • ALOGS: -3.85
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1996 FDA
Aug. 1, 1999 PMDA PFIZER JAPAN INC.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood growth hormone increased 180.98 17.41 34 8240 436 63480312
Insulin-like growth factor increased 163.91 17.41 35 8239 884 63479864
Aortic valve incompetence 114.42 17.41 39 8235 5949 63474799
Insulin-like growth factor decreased 105.26 17.41 21 8253 375 63480373
Pulmonary pain 104.63 17.41 32 8242 3458 63477290
Ovarian hyperstimulation syndrome 88.02 17.41 29 8245 3985 63476763
Pituitary tumour 81.89 17.41 20 8254 928 63479820
Blood prolactin increased 75.57 17.41 25 8249 3478 63477270
Amyloid arthropathy 69.77 17.41 16 8258 564 63480184
Needle issue 67.51 17.41 31 8243 10345 63470403
Coronary artery dissection 63.47 17.41 16 8258 846 63479902
Blood prolactin decreased 62.42 17.41 10 8264 45 63480703
Mitral valve incompetence 56.64 17.41 34 8240 19560 63461188
Pituitary haemorrhage 50.41 17.41 9 8265 85 63480663
Empty sella syndrome 50.12 17.41 8 8266 35 63480713
Pituitary tumour benign 46.10 17.41 15 8259 1980 63478768
Inappropriate schedule of product administration 44.46 17.41 61 8213 103904 63376844
Prolactin-producing pituitary tumour 42.40 17.41 8 8266 105 63480643
Acromegaly 39.32 17.41 7 8267 65 63480683
Cardiac valve disease 38.38 17.41 16 8258 4236 63476512
Mediastinal fibrosis 38.23 17.41 6 8268 23 63480725
Compulsive shopping 36.27 17.41 10 8264 749 63479999
Tricuspid valve incompetence 36.22 17.41 23 8251 14598 63466150
Bite 35.77 17.41 9 8265 472 63480276
Diabetes mellitus 33.83 17.41 39 8235 55771 63424977
Pneumocephalus 32.92 17.41 7 8267 173 63480575
Blood pressure increased 32.76 17.41 68 8206 161994 63318754
Cerebrospinal fluid leakage 31.83 17.41 10 8264 1180 63479568
Gambling disorder 31.33 17.41 10 8264 1242 63479506
Injection site mass 31.14 17.41 23 8251 18633 63462115
Cholelithiasis 30.58 17.41 33 8241 43892 63436856
Overweight 30.15 17.41 13 8261 3738 63477010
Hypogonadism 30.08 17.41 6 8268 107 63480641
Urine calcium/creatinine ratio increased 29.72 17.41 6 8268 114 63480634
Hemianopia heteronymous 28.22 17.41 5 8269 45 63480703
Mastitis 27.50 17.41 11 8263 2621 63478127
Abortion spontaneous 26.97 17.41 32 8242 47163 63433585
Neoplasm progression 26.47 17.41 28 8246 36400 63444348
Urethral caruncle 25.35 17.41 5 8269 84 63480664
Delusion 25.12 17.41 17 8257 12000 63468748
Death 24.67 17.41 9 8265 374372 63106376
Kounis syndrome 24.41 17.41 9 8265 1721 63479027
Camptocormia 24.07 17.41 6 8268 303 63480445
Aortic valve sclerosis 23.67 17.41 8 8266 1188 63479560
Body temperature decreased 23.11 17.41 20 8254 20299 63460449
Blood growth hormone abnormal 22.78 17.41 4 8270 34 63480714
Blood parathyroid hormone increased 22.69 17.41 10 8264 3028 63477720
Ovarian rupture 22.29 17.41 4 8270 39 63480709
Toxicity to various agents 22.15 17.41 3 8271 247247 63233501
Infusion related reaction 21.95 17.41 3 8271 245518 63235230
Dopamine dysregulation syndrome 21.84 17.41 5 8269 175 63480573
Obesity 21.72 17.41 23 8251 29929 63450819
Blood thyroid stimulating hormone decreased 21.63 17.41 11 8263 4579 63476169
Chikungunya virus infection 21.49 17.41 5 8269 188 63480560
Hormone level abnormal 21.26 17.41 9 8265 2474 63478274
Injection site pain 21.17 17.41 50 8224 129750 63350998
Application site mass 21.16 17.41 4 8270 53 63480695
Nervousness 21.08 17.41 23 8251 30956 63449792
Panic disorder 20.75 17.41 9 8265 2624 63478124
Nocturia 20.65 17.41 13 8261 8128 63472620
Injection site hypertrophy 20.46 17.41 4 8270 64 63480684
Blood sodium increased 20.43 17.41 9 8265 2723 63478025
Hyperprolactinaemia 20.31 17.41 10 8264 3890 63476858
Memory impairment 20.18 17.41 43 8231 104215 63376533
Hypopituitarism 20.07 17.41 7 8267 1141 63479607
Arteriovenous fistula 19.75 17.41 5 8269 269 63480479
Galactorrhoea 19.71 17.41 10 8264 4145 63476603
Dengue fever 19.60 17.41 6 8268 649 63480099
Neoplasm 19.31 17.41 12 8262 7333 63473415
Pituitary tumour recurrent 19.21 17.41 4 8270 89 63480659
Blood pressure systolic increased 19.03 17.41 27 8247 47370 63433378
Blood gonadotrophin decreased 19.01 17.41 3 8271 12 63480736
Adjacent segment degeneration 19.01 17.41 3 8271 12 63480736
Hypothalamo-pituitary disorder 18.78 17.41 6 8268 747 63480001
Secondary hypogonadism 18.73 17.41 4 8270 101 63480647
Pituitary tumour removal 18.30 17.41 3 8271 16 63480732
Vitamin B12 decreased 18.01 17.41 9 8265 3611 63477137
Mitral valve disease 18.00 17.41 8 8266 2472 63478276
Normal newborn 17.91 17.41 12 8262 8329 63472419
Infection 17.87 17.41 4 8270 229169 63251579
Multiple endocrine neoplasia Type 1 17.86 17.41 3 8271 19 63480729
Mitral valve sclerosis 17.81 17.41 4 8270 128 63480620
Headache 17.81 17.41 142 8132 633099 62847649
Insulin-like growth factor abnormal 17.73 17.41 3 8271 20 63480728

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrospinal fluid leakage 260.44 21.88 48 5053 488 34951342
Gambling disorder 180.12 21.88 43 5058 1617 34950213
Insulin-like growth factor increased 139.01 21.88 33 5068 1210 34950620
Aortic valve incompetence 103.11 21.88 37 5064 5867 34945963
Pneumocephalus 81.38 21.88 15 5086 152 34951678
Radiation inflammation 80.58 21.88 20 5081 885 34950945
Mitral valve incompetence 78.69 21.88 40 5061 14903 34936927
Visual pathway disorder 75.14 21.88 11 5090 19 34951811
Pulmonary pain 74.58 21.88 20 5081 1204 34950626
Pituitary haemorrhage 72.47 21.88 14 5087 186 34951644
Needle issue 62.42 21.88 26 5075 6139 34945691
Empty sella syndrome 53.14 21.88 9 5092 53 34951777
Secondary hypogonadism 49.78 21.88 11 5090 291 34951539
Blood growth hormone increased 47.03 21.88 11 5090 377 34951453
Cardiac valve disease 45.03 21.88 17 5084 3101 34948729
Jealous delusion 43.94 21.88 10 5091 303 34951527
Neoplasm progression 43.22 21.88 32 5069 23268 34928562
Prolactin-producing pituitary tumour 43.18 21.88 7 5094 30 34951800
Pituitary tumour 42.81 21.88 11 5090 560 34951270
Impulse-control disorder 42.15 21.88 13 5088 1288 34950542
Hormone level abnormal 41.23 21.88 10 5091 401 34951429
Acromegaly 40.80 21.88 7 5094 45 34951785
Hypersexuality 36.34 21.88 12 5089 1481 34950349
Intracranial hypotension 35.36 21.88 8 5093 236 34951594
Tricuspid valve incompetence 34.30 21.88 20 5081 9740 34942090
Cortisol free urine increased 34.02 21.88 5 5096 9 34951821
Pleural effusion 33.82 21.88 50 5051 81496 34870334
Pleural fibrosis 33.22 21.88 11 5090 1369 34950461
Glucose tolerance decreased 31.54 21.88 6 5095 73 34951757
Gambling 31.19 21.88 7 5094 199 34951631
Schizophrenia 31.09 21.88 18 5083 8648 34943182
Arthropathy 30.99 21.88 28 5073 26879 34924951
Lung neoplasm malignant 30.27 21.88 23 5078 17372 34934458
Blood corticotrophin increased 29.84 21.88 6 5095 99 34951731
Injection site erosion 29.56 21.88 6 5095 104 34951726
Injection site pain 29.02 21.88 32 5069 38973 34912857
Death 29.00 21.88 11 5090 398038 34553792
Therapeutic response decreased 28.94 21.88 28 5073 29285 34922545
Knee arthroplasty 28.15 21.88 16 5085 7428 34944402
Priapism 28.12 21.88 14 5087 4980 34946850
Hemianopia 27.06 21.88 8 5093 686 34951144
Autoimmune thyroiditis 26.83 21.88 9 5092 1165 34950665
Borderline personality disorder 26.75 21.88 7 5094 383 34951447
Dopamine dysregulation syndrome 25.66 21.88 7 5094 449 34951381
Carcinoid tumour 24.95 21.88 6 5095 232 34951598
IIIrd nerve paralysis 24.73 21.88 7 5094 515 34951315
Renal haematoma 24.63 21.88 7 5094 522 34951308
Blood prolactin increased 23.27 21.88 9 5092 1751 34950079
Persecutory delusion 23.18 21.88 10 5091 2570 34949260
Oncologic complication 22.70 21.88 6 5095 341 34951489
Aortic valve disease 22.43 21.88 8 5093 1243 34950587

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrospinal fluid leakage 236.54 15.56 54 11701 1645 79730988
Insulin-like growth factor increased 230.93 15.56 54 11701 1832 79730801
Blood growth hormone increased 178.95 15.56 37 11718 699 79731934
Pulmonary pain 175.89 15.56 52 11703 4421 79728212
Aortic valve incompetence 163.07 15.56 59 11696 9471 79723162
Gambling disorder 156.26 15.56 40 11715 1986 79730647
Pneumocephalus 117.11 15.56 23 11732 331 79732302
Needle issue 114.85 15.56 50 11705 13018 79719615
Pituitary haemorrhage 113.89 15.56 22 11733 289 79732344
Mitral valve incompetence 109.10 15.56 62 11693 28503 79704130
Insulin-like growth factor decreased 89.03 15.56 20 11735 565 79732068
Pituitary tumour 88.74 15.56 23 11732 1199 79731434
Blood prolactin increased 88.43 15.56 30 11725 3981 79728652
Ovarian hyperstimulation syndrome 83.83 15.56 28 11727 3543 79729090
Empty sella syndrome 82.73 15.56 14 11741 81 79732552
Acromegaly 80.68 15.56 14 11741 96 79732537
Radiation inflammation 80.35 15.56 20 11735 885 79731748
Visual pathway disorder 70.25 15.56 12 11743 74 79732559
Amyloid arthropathy 67.81 15.56 16 11739 564 79732069
Tricuspid valve incompetence 65.24 15.56 39 11716 19673 79712960
Cardiac valve disease 60.52 15.56 25 11730 5716 79726917
Prolactin-producing pituitary tumour 59.25 15.56 11 11744 115 79732518
Coronary artery dissection 57.02 15.56 16 11739 1128 79731505
Secondary hypogonadism 52.82 15.56 12 11743 357 79732276
Intracranial hypotension 51.39 15.56 12 11743 404 79732229
Hormone level abnormal 48.19 15.56 16 11739 1986 79730647
Blood pressure increased 46.81 15.56 99 11656 211261 79521372
Neoplasm progression 46.21 15.56 47 11708 51635 79680998
Pituitary tumour benign 44.24 15.56 16 11739 2560 79730073
Diabetes mellitus 44.02 15.56 56 11699 78334 79654299
Toxicity to various agents 42.25 15.56 6 11749 421534 79311099
Death 41.27 15.56 16 11739 566498 79166135
Blood growth hormone abnormal 41.00 15.56 7 11748 43 79732590
Acute kidney injury 40.69 15.56 13 11742 519391 79213242
Knee arthroplasty 39.88 15.56 40 11715 43208 79689425
Dopamine dysregulation syndrome 38.85 15.56 10 11745 507 79732126
Injection site pain 38.73 15.56 69 11686 129769 79602864
Mediastinal fibrosis 38.14 15.56 6 11749 20 79732613
Jealous delusion 38.04 15.56 9 11746 321 79732312
Syndactyly 33.91 15.56 7 11748 131 79732502
Gambling 33.63 15.56 8 11747 292 79732341
Bite 33.57 15.56 9 11746 535 79732098
Obesity 33.33 15.56 33 11722 35092 79697541
Glucose tolerance decreased 31.26 15.56 6 11749 76 79732557
Injection site mass 31.21 15.56 25 11730 20159 79712474
Inappropriate schedule of product administration 31.20 15.56 64 11691 133564 79599069
Hypersexuality 30.98 15.56 11 11744 1669 79730964
Delusion 30.95 15.56 25 11730 20398 79712235
Pituitary enlargement 30.84 15.56 6 11749 82 79732551
Mitral valve disease 30.60 15.56 13 11742 3184 79729449
Pleural fibrosis 30.39 15.56 14 11741 4153 79728480
Aortic valve sclerosis 30.36 15.56 11 11744 1769 79730864
Intentional product misuse 30.22 15.56 52 11703 95113 79637520
Neoplasm 30.06 15.56 18 11737 9098 79723535
Compulsive shopping 29.96 15.56 9 11746 807 79731826
Priapism 29.35 15.56 14 11741 4491 79728142
Cardiomegaly 29.26 15.56 27 11728 26325 79706308
Injection site erosion 27.97 15.56 6 11749 136 79732497
Reversible cerebral vasoconstriction syndrome 27.84 15.56 12 11743 3045 79729588
Urine calcium/creatinine ratio increased 27.72 15.56 6 11749 142 79732491
Visual field defect 27.62 15.56 17 11738 9028 79723605
Body temperature decreased 26.50 15.56 28 11727 32117 79700516
Headache 26.04 15.56 175 11580 653597 79079036
Tricuspid valve disease 25.96 15.56 7 11748 425 79732208
Aortic valve disease 25.83 15.56 10 11745 1931 79730702
Heart rate decreased 25.79 15.56 41 11714 70275 79662358
Carotid aneurysm rupture 25.51 15.56 4 11751 13 79732620
Urethral caruncle 25.32 15.56 5 11750 74 79732559
Hallucination 24.83 15.56 45 11710 85700 79646933
Blood pressure systolic increased 24.48 15.56 39 11716 66947 79665686
Drug abuse 23.86 15.56 65 11690 162626 79570007
Blood prolactin decreased 23.79 15.56 6 11749 280 79732353
Cardiac valve sclerosis 23.37 15.56 5 11750 112 79732521
Impulse-control disorder 23.11 15.56 9 11746 1765 79730868
Oncologic complication 22.75 15.56 6 11749 335 79732298
Ovarian rupture 22.62 15.56 4 11751 31 79732602
Persecutory delusion 22.43 15.56 12 11743 4897 79727736
Blindness 22.12 15.56 24 11731 28359 79704274
Sleep apnoea syndrome 21.97 15.56 27 11728 36451 79696182
Renal haematoma 21.58 15.56 7 11748 808 79731825
Schizophrenia 21.51 15.56 18 11737 15422 79717211
Infusion related reaction 21.42 15.56 4 11751 230233 79502400
Lower respiratory tract infection 21.37 15.56 54 11701 129166 79603467
Mastitis 21.27 15.56 9 11746 2182 79730451
Cholelithiasis 21.11 15.56 32 11723 52632 79680001
Cortisol free urine increased 21.04 15.56 4 11751 48 79732585
Pituitary tumour recurrent 20.88 15.56 5 11750 188 79732445
Lung neoplasm malignant 20.79 15.56 23 11732 27769 79704864
Rheumatoid arthritis 20.78 15.56 3 11752 208467 79524166
Camptocormia 20.62 15.56 6 11749 482 79732151
Sepsis 20.61 15.56 7 11748 269421 79463212
Blood testosterone decreased 20.57 15.56 9 11746 2368 79730265
Drug resistance 20.36 15.56 28 11727 42185 79690448
Hyperprolactinaemia 20.16 15.56 11 11744 4665 79727968
Pneumonia 20.16 15.56 42 11713 660204 79072429
Carcinoid tumour 19.83 15.56 6 11749 551 79732082
Pleural effusion 19.30 15.56 56 11699 145206 79587427
Injection site hypertrophy 19.27 15.56 4 11751 77 79732556
Adenoma benign 19.17 15.56 7 11748 1151 79731482
Mitral valve sclerosis 19.14 15.56 5 11750 269 79732364
IIIrd nerve paralysis 18.97 15.56 7 11748 1186 79731447
Hypothalamo-pituitary disorder 18.96 15.56 7 11748 1187 79731446
Performance enhancing product use 18.89 15.56 4 11751 85 79732548
Arthropathy 18.66 15.56 63 11692 177048 79555585
Adjacent segment degeneration 18.64 15.56 3 11752 12 79732621
Hemianopia heteronymous 18.51 15.56 4 11751 94 79732539
Autoimmune thyroiditis 18.37 15.56 10 11745 4223 79728410
Normal newborn 18.37 15.56 12 11743 7060 79725573
Product dose omission issue 17.82 15.56 78 11677 247459 79485174
Movement disorder 17.76 15.56 21 11734 27238 79705395
Mass 17.67 15.56 17 11738 17455 79715178
Blood cholesterol abnormal 17.62 15.56 9 11746 3341 79729292
Genital pain 17.59 15.56 6 11749 808 79731825
Memory impairment 16.73 15.56 45 11710 111689 79620944
Drug hypersensitivity 16.50 15.56 12 11743 298904 79433729
Hemianopia 16.45 15.56 7 11748 1721 79730912
Tumour compression 16.32 15.56 4 11751 166 79732467
Thyroid mass 16.14 15.56 9 11746 3981 79728652
Treatment failure 15.78 15.56 3 11752 170483 79562150
Cortisol increased 15.74 15.56 5 11750 540 79732093
Blood corticotrophin increased 15.71 15.56 4 11751 194 79732439
Brain neoplasm 15.70 15.56 10 11745 5636 79726997

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G02CB03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Prolactine inhibitors
ATC N04BC06 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA CS M0007652 Ergolines
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:51065 Dopamine receptor agonist
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175827 Ergot Derivative

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperprolactinemia indication 237662005 DOID:12700
Prevention of ovarian hyperstimulation syndrome indication
Heart valve disorder contraindication 368009 DOID:4079
Severe pre-eclampsia contraindication 46764007
Retroperitoneal fibrosis contraindication 49120005
Fibrosis of lung contraindication 51615001 DOID:3770
Fibrosis of pericardium contraindication 194965002
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Hypertensive urgency contraindication 443482000
Occlusive Vascular Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.83 acidic
pKa2 13.48 acidic
pKa3 7.88 Basic
pKa4 5.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.20 IUPHAR CHEMBL
Alpha-2A adrenergic receptor GPCR ANTAGONIST Ki 7.90 IUPHAR
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 2A GPCR AGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 2B GPCR Ki 8.85 CHEMBL
5-hydroxytryptamine receptor 2C GPCR AGONIST Ki 6.20 IUPHAR
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 6.50 IUPHAR
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 7.10 IUPHAR
D(3) dopamine receptor GPCR AGONIST Ki 9.10 IUPHAR
D(1B) dopamine receptor GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.30 IUPHAR
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.10 IUPHAR
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
D(4) dopamine receptor GPCR AGONIST Ki 7.30 IUPHAR
Alpha-1D adrenergic receptor GPCR Ki 6.78 PDSP
D(1A) dopamine receptor GPCR AGONIST Ki 6.70 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.22 PDSP

External reference:

IDSource
4021014 VUID
N0000148483 NUI
D00987 KEGG_DRUG
134895 RXNORM
C0107994 UMLSCUI
CHEBI:3286 CHEBI
CHEMBL1201087 ChEMBL_ID
D000077465 MESH_DESCRIPTOR_UI
DB00248 DRUGBANK_ID
37 IUPHAR_LIGAND_ID
5860 INN_ID
LL60K9J05T UNII
54746 PUBCHEM_CID
4317 MMSL
6425 MMSL
73532 MMSL
d04112 MMSL
109139002 SNOMEDCT_US
386979007 SNOMEDCT_US
4021014 VANDF
005446 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 0093-5420 TABLET 0.50 mg ORAL ANDA 25 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 0093-5420 TABLET 0.50 mg ORAL ANDA 25 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 23155-823 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 23155-823 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 49884-673 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3157 TABLET 0.50 mg ORAL ANDA 25 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3951 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-5834 TABLET 0.50 mg ORAL ANDA 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-5834 TABLET 0.50 mg ORAL ANDA 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-6596 TABLET 0.50 mg ORAL ANDA 11 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50742-118 TABLET 0.50 mg ORAL ANDA 23 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 59762-1005 TABLET 0.50 mg ORAL NDA AUTHORIZED GENERIC 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 59762-1005 TABLET 0.50 mg ORAL NDA AUTHORIZED GENERIC 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 70512-860 TABLET 0.50 mg ORAL ANDA 22 sections